Integra LifeSciences Holdings Corporation

NasdaqGS:IART Stock Report

Market Cap: US$2.5b

Integra LifeSciences Holdings Past Earnings Performance

Past criteria checks 1/6

Integra LifeSciences Holdings has been growing earnings at an average annual rate of 17%, while the Medical Equipment industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 1.5% per year. Integra LifeSciences Holdings's return on equity is 4.3%, and it has net margins of 4.4%.

Key information

17.0%

Earnings growth rate

17.6%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate1.5%
Return on equity4.3%
Net Margin4.4%
Next Earnings Update25 Apr 2024

Recent past performance updates

Recent updates

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24
Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19
Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05
Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26
Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14
At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27
Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Feb 02
Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Jan 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

Dec 21
Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Dec 08
When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

Oct 19
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Oct 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Integra LifeSciences: Wide Dislocation In Fundamentals Vs. Market Value

Sep 13

Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 06
Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

FDA labels recall of intracranial pressure monitors by Integra as most serious

Aug 31

Integra Lifesciences voluntarily recalls pressure monitors, lowers revenue, profit guidance

Aug 24

Returns At Integra LifeSciences Holdings (NASDAQ:IART) Appear To Be Weighed Down

Aug 23
Returns At Integra LifeSciences Holdings (NASDAQ:IART) Appear To Be Weighed Down

Integra LifeSciences founder/former CEO dies

Aug 16

Integra LifeSciences Holdings GAAP EPS of $0.54 beats by $0.09, revenue of $398M beats by $2.62M

Jul 27

Is There An Opportunity With Integra LifeSciences Holdings Corporation's (NASDAQ:IART) 47% Undervaluation?

Jul 20
Is There An Opportunity With Integra LifeSciences Holdings Corporation's (NASDAQ:IART) 47% Undervaluation?

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Jul 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Revenue & Expenses Breakdown
Beta

How Integra LifeSciences Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:IART Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,5426859383
30 Sep 231,54310159484
30 Jun 231,54513161487
31 Mar 231,56217261584
31 Dec 221,55818161482
30 Sep 221,56517362581
30 Jun 221,56716661982
31 Mar 221,55915761479
31 Dec 211,54216963793
30 Sep 211,52621660474
30 Jun 211,50920659772
31 Mar 211,37817055568
31 Dec 201,37213459577
30 Sep 201,3785657377
30 Jun 201,387-358478
31 Mar 201,5122762381
31 Dec 191,5185068880
30 Sep 191,5066060874
30 Jun 191,49310161075
31 Mar 191,4758360876
31 Dec 181,4726169178
30 Sep 181,4588060775
30 Jun 181,3717057270
31 Mar 181,2876954666
31 Dec 171,1886551763
30 Sep 171,0754947560
30 Jun 171,0476646060
31 Mar 171,0146844659
31 Dec 169927543158
30 Sep 169856142657
30 Jun 16958941556
31 Mar 16919939553
31 Dec 15883737750
30 Sep 158541236047
30 Jun 158275334644
31 Mar 157824632542
31 Dec 147973633543
30 Sep 147983034547
30 Jun 14814-1035649
31 Mar 14855-1338051
31 Dec 136972230542
30 Sep 13830-2237350
30 Jun 138272136550

Quality Earnings: IART has a large one-off loss of $147.7M impacting its last 12 months of financial results to 31st December, 2023.

Growing Profit Margin: IART's current net profit margins (4.4%) are lower than last year (11.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IART's earnings have grown by 17% per year over the past 5 years.

Accelerating Growth: IART's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: IART had negative earnings growth (-62.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (3.3%).


Return on Equity

High ROE: IART's Return on Equity (4.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.